IMA Kerala Medical Journal

  • Home
  • AI Submit
  • Current Issue
  • Guidelines
  • Editorial Board
  • Archives
  • Contact

Tigecycline- A New Tetracycline Derivative for MRSA Infection

Drug Profile, Volume 01 Issue 2 – October to December 2008

Authors

Dr. Rema MN, MD, Professor & HOD, Department of Pharmacology, Amala Institute of Medical Science; President, TC Medical Council


Abstract

Introduction: The inevitable consequence of the widespread use of antimicrobial agents has been the emergence of antibiotic-resistant pathogens, fueling an ever-increasing need for new antimicrobial agents.
Methodology: The clinical use and therapeutic effects of the new drug Tigecycline is described.
Result: Tigecycline is an example of a new drug developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was approved by FDA in 2005


Full Article

Download Full Article (PDF)

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Search

Recent Articles

  • Challenging Cholesterol
  • Problems in the Implementation of Biomedical Waste Management Programme at Government Medical College Hospital, Thiruvananthapuram – A Qualitative Study
  • Do We Achieve target Lipid Levels with Statins in Patients with Coronary Artery Disease?
  • Clinico-Pathology Study of Vitellointestinal Remnants in Children
  • Understanding Depressive Disorders
  • Interstitial Pneumonia in Chikungunya Infection
  • Re-expansion Pulmonary Oedema
  • Mobile Phones and Health Hazards
  • Sitagliptin: The First in a New Class of DPP-4 Inhibitors for the Treatment of Type 2 Diabetes
  • Smoking Cessation: Initial Insights into a New Drug

Kerala Medical Journal All Rights Reserved | Powered by New Clinician